Regulating Contrast Agents as Drugs: What’s Next for FDA?
Update Magazine | Summer 2023
Product Testing, Questionable Science, and the Smallest, Big Developments in Consumer Product Litigation
Update Magazine | Summer 2023
FTC and NAD Remind Industry of Their Authority Over All Health Product Advertising (Including Rx)
Update Magazine | Spring 2023
FDA Amends Final Ruling for Yogurt Standard of Identity
Update Magazine | Spring 2023
MoCRA Is Here—Now What? Unpacking Litigation and Regulatory Risk for Cosmetics Brands Following MoCRA’s Enactment
Update Magazine | Spring 2023
An Overview of Food and Drug Law Practices, 2023 Update
Update Magazine | Spring 2023
Association of Clinical Research Professionals’ Response to FDA Draft Guidance on Diversity in Clinical Trials: Increased Diversity Should Be a Requirement, Not a Suggestion GalleryAssociation of Clinical Research Professionals’ Response to FDA Draft Guidance on Diversity in Clinical Trials: Increased Diversity Should Be a Requirement, Not a Suggestion
Association of Clinical Research Professionals’ Response to FDA Draft Guidance on Diversity in Clinical Trials: Increased Diversity Should Be a Requirement, Not a Suggestion
Update Magazine | Spring 2023
Establishing an FDA office in the Middle East/North Africa: An Abraham Accords Initiative
Update Magazine | Spring 2023
Direct-to-Patient Sample Distribution in the Time of COVID-19
Update Magazine | Winter 2022
Federal Funding of Medical Countermeasures: Opportunities, Risks, and Enforcement Trends
Update Magazine | Winter 2022
